NU Skin Admitted Illegal Sales In China to U.S. SEC
This article was originally published in PharmAsia News
After exposure in the media, Nu Skin acknowledged that the company discovered illegal behavior by some dealers who did not comply with applicable regulations, and the company promised to correct the situation.
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.